Show simple item record

dc.contributor.authorAlonso Alconada, Lorena
dc.contributor.authorBarbazan, Jorge
dc.contributor.authorCandamio, Sonia
dc.contributor.authorFalco, Josep Lluis
dc.contributor.authorAntón Rodríguez, Cristina 
dc.contributor.authorMartín Saborido, Carlos 
dc.contributor.authorFuster, Gustavo
dc.contributor.authorSampedro, Mabel
dc.contributor.authorGrande, Carlos
dc.contributor.authorLado, Rubén
dc.contributor.authorSampietro Colom, Laura
dc.contributor.authorCrego, Eladio
dc.contributor.authorFigueiras, Sergio
dc.contributor.authorLeón Mateos, Luis
dc.contributor.authorLópez López, Rafael
dc.contributor.authorAbal, Miguel
dc.date.accessioned2017-11-17T07:56:29Z
dc.date.available2017-11-17T07:56:29Z
dc.date.issued2017
dc.identifier.issn1699-3055
dc.identifier.urihttp://hdl.handle.net/10641/1365
dc.description.abstractPurpose: Management of metastatic disease in oncology includes monitoring of therapy response principally by imaging techniques like CT-Scan. In addition to some limitations, the irruption of liquid biopsy and its application in personalized medicine has encouraged the development of more efficient technologies for prognosis and follow-up of patients in advanced disease. Methods: PrediCTC constitutes a panel of genes for the assessment of Circulating Tumor Cells (CTC) in metastatic colorectal cancer patients, with demonstrated improved efficiency compared to CT-Scan for the evaluation of early therapy response in a multicenter prospective study. In this work, we designed and developed a technology transfer strategy to define the market opportunity for an eventual implementation of PrediCTC in the clinical practice. Results: This included the definition of the regulatory framework, the analysis of the regulatory roadmap needed for CE mark, a benchmarking study, the design of a product development strategy, a revision of intellectual property, a cost-effectiveness study and an expert panel consultation. Conclusion: The definition and analysis of an appropriate technology transfer strategy and the correct balance among regulatory, financial and technical determinants are critical for the transformation of a promising technology into a viable technology, and for the decision of implementing liquid biopsy in the monitoring of therapy response in advanced disease.spa
dc.language.isoengspa
dc.publisherClinical and Translational Oncologyspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectLiquid biopsyspa
dc.subjectMetastatic colorectal cancerspa
dc.subjectRegulatory roadmapspa
dc.subjectBenchmarkingspa
dc.subjectProduct developmentspa
dc.subjectIntellectual propertyspa
dc.subjectCost-effectivenessspa
dc.subjectExpert panelspa
dc.titlePrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system.spa
dc.typearticlespa
dc.description.versionpre-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent533 KBspa


Files in this item

FilesSizeFormatView
Alonso-ALconada et al., Revised ...532.6KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España